We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Aggressive Induction and Concurrent Chemoradiation Pays Off in Advanced NSCLC

Aug 1, 2002
Volume: 
11
Issue: 
8
  • Lung Cancer

ORLANDO, Florida—An aggressive strategy of induction and concurrent
chemoradiotherapy was feasible and well tolerated in a North Carolina study of
advanced non-small-cell lung cancer (NSCLC) patients, reported Mark A.
Socinski, MD, director of both the Multidisciplinary Thoracic Oncology Program
and the Clinical Trials Program, University of North Carolina, Chapel Hill (ASCO
abstract 1266).

"This is a population of patients that is potentially curable, but with
standard treatment approaches we only cure 15% to 20%." Dr. Socinski
pointed out. "The main problems are local and distant failure, so in this
study we incorporated more aggressive systemic therapy with a triplet, and gave
more aggressive locoregional therapy in terms of dose escalation with
concurrent therapy," he added.

‘Thinking Outside the Box’

The investigators previously demonstrated that induction and concurrent
carboplatin (Paraplatin) and paclitaxel with thoracic conformal radiation
therapy (TCRT) to a total dose of 74 Gy is tolerable and associated with
favorable survival outcomes. Patients receiving this regimen achieved a median
survival of 26 months and 1-year survival of 40%. (Cancer 92:1213-1223, 2001).
Analysis of the pattern of failure suggested that both locoregional and distant
failures were problematic; therefore, a more aggressive regimen was
incorporated into a subsequent trial.

Dr. Socinski said this approach reflects the benefit of "thinking
outside the box."

"We’ve been stuck with using 60 to 66 Gy, and we know this doesn’t
provide locoregional control as well as it should," he said.
"Therefore, we think this escalation of dose may be more effective."

The current regimen involved the triplet of carboplatin/irinotecan (CPT-11,
Camptosar)/paclitaxel supported by granulocyte colony-stimulating factor (G-CSF,
filgrastim [Neupogen]) as induction therapy, followed on day 43 by concurrent
carboplatin/paclitaxel and dose-escalated TCRT.

Pages

  • 1
  • 2
  • next ›
  • last »

Related Articles

  • Neoadjuvant Nivolumab Yields High Response in Newly Diagnosed NSCLC
  • Pembrolizumab Plus Chemo Improved Survival in Advanced NSCLC
  • Epacadostat/Durvalumab Combo Well Tolerated in Solid Tumor Trial
  • Antibiotics Reduced Efficacy of Checkpoint Inhibitors in RCC, NSCLC
  • Systemic Treatment Options for Brain Metastases from Non–Small-Cell Lung Cancer

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.